Canadian-based Oncolytics Biotech is focused on the novel approach of developing oncolytic viruses as potential therapeutics for patients afflicted with various types of cancer, including lung, pancreatic, and colorectal cancers. The company’s clinical program includes a Phase III trial in head and neck cancer using REOLYSIN, its proprietary formulation of the human reovirus.
The company today announced that it has completed its 36 patient enrollment in its U.K. Phase I clinical trial using intravenously-administered REOLYSIN in combination with cyclophosphamide in patients with advanced malignancies. Eligible patients include those who have been diagnosed with advanced or metastatic solid tumors. These include patients with pancreatic, lung, and ovarian cancers that don’t respond to standard therapy, or for which no standard curative therapy exists.
The study will examine the potential of cylcophosphamide to modulate the immune system’s response to REOLYSIN. The primary objective of the open label, dose-escalating, non-randomized Phase I study is to determine the minimum effective immunomodulastory dosage of cyclophosphamide necessary to obtain successful immune modulation to combat the cancer. Secondary aims of the trial include assessing the safety profile of the combination and gathering any evidence of anti-tumor activity from this drug combination.
The market for much needed cancer therapies is large, offering Oncolytics quite an opportunity. The American Cancer Society estimates there will be more than 1.6 million new cancer cases diagnosed in the U.S. alone in 2012. The U.S. National Institutes of Health estimated than even five years ago, the direct medical cost associated with cancer was in excess of $100 billion.
For additional information about Oncolytics Biotech and REOLYSIN, please visit the company’s website at www.oncolyticsbiotech.com
Let us hear your thoughts below: